This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). lisdexamfetamine dimesylate (Elvanse®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 188. 2013
Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders.
Subject indexing assigned by CRD
Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published